Arrhythmogenic right ventricular cardiomyopathy vs. dilated cardiomyopathy: implications for next-generation sequencing and microRNA regulation in appropriate diagnosis —Authors' reply

We thank Salvatore Patan è and Francesco Patanè1 for their accurate comments on our article.2 As they well pointed out, it is indeed relevant the recent advances in the micro RNA (miRNA) field and the recent discovery of the potential roll of several miRNAs in arrhythmogenic right ventricular cardiomyopathy (ARVC).3 The analysis of miRNA was out of the scope of our article, but we recognize the value of this molecules in the mechanism of the disease and their putative roll as target for novel therapies not only for ARVC but also for all cardiomyopathies.4 Interestingly, miRNAs could also be used as biomarkers to predict the risk for sudden cardiac death.5 However, the precise mechanism of this miRNA has not yet been validated3 in ARVC, and although we can find very promising and exiting data, this has not been translated yet to the clinical practice.
Source: Europace - Category: Cardiology Source Type: research